
Liposomal DOXOrubicin - HIV - positive Kaposi's Sarcoma

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

- * Surname:
- * Given Name:
- * OHIN: * Chart Number:
- * Postal Code:
- * Height (cm): * Weight (kg):
- * BSA (m²): * Gender: Male Female Other
- * Date of Birth:
Day Month Year
- * Site:
- * Attending Physician (MRP- Most Responsible Physician):
- Requested Prior Approval Yes * Patient on Clinical Trial Yes No
- Other (specify):
- Specify Arm:
 Standard of care arm Experimental arm
 Blinded / Unknown

Request prior approval for enrolment

- * Justification for Funding
-

2. Eligibility Criteria

The patient must meet the following criteria:

- a. Patient has HIV-positive Kaposi's sarcoma Yes

b. Patient visceral Kaposi's sarcoma
has: progressive disease despite prior therapy with vinblastine or interferon

c. Patient
has:
 signs of peripheral neuropathy or is believed to be at high risk of neuropathy
 other medical condition that makes it inappropriate to use standard combination chemotherapy.

Please specify the nature of the condition:

.....

d. ECOG performance status is 0- 0 1 2
2:

3. Funded Dose

- Liposomal doxorubicin is 20 mg/m² every 2 weeks

4. Supporting Documents

To ensure reimbursement of your claim, both the completed enrolment form and a copy of the required documentation (where applicable) must be submitted through CCO e-Claims.

Signature of Attending Physician (MRP-Most Responsible Physician):

.....
Day Month Year